XERS (Xeris Biopharma Holdings) Total Assets: $392.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XERS Xeris Biopharma Holdings Inc XERS
71 GF Score
Price $8.55
GF Value $5.20
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Xeris Biopharma Holdings Total Assets?

Xeris Biopharma Holdings XERS +3.39% 71 Total Assets is $392.0 Mil as of Mar. 2026. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.20 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Xeris Biopharma Holdings's Total Assets for the quarter that ended in Mar. 2026 was $392.0 Mil.

Warning Sign:

If a company builds assets at 43.5% a year, faster than its revenue growth rate of 29.5% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Xeris Biopharma Holdings's average Total Assets Growth Rate was 9.00% per year. During the past 3 years, the average Total Assets Growth Rate was 7.00% per year. During the past 5 years, the average Total Assets Growth Rate was 43.50% per year.

During the past 10 years, Xeris Biopharma Holdings's highest 3-Year average Total Assets Growth Rate was 201.10%. The lowest was 7.00%. And the median was 104.80%.

Total Assets is connected with ROA %. Xeris Biopharma Holdings's annualized ROA % for the quarter that ended in Mar. 2026 was 2.30%. Total Assets is also linked to Revenue through Asset Turnover. Xeris Biopharma Holdings's Asset Turnover for the quarter that ended in Mar. 2026 was 0.21.

Xeris Biopharma Holdings  (NAS:XERS) Total Assets Explanation

Total Assets is connected with ROA %.

Xeris Biopharma Holdings's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=8.936/( (383.527+392.013)/ 2 )
=8.936/387.77
=2.30 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Xeris Biopharma Holdings's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=83.127/( (383.527+392.013)/ 2 )
=83.127/387.77
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Xeris Biopharma Holdings Total Assets Related Terms

Xeris Biopharma Holdings Total Assets Historical Data

* Premium members only.

The historical data trend for Xeris Biopharma Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xeris Biopharma Holdings Total Assets Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 304.36 344.52 322.60 323.06 383.53

Xeris Biopharma Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 315.45 334.69 370.19 383.53 392.01
XERS
71GF Score
Xeris Biopharma Holdings Inc XERS
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xeris Biopharma Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Xeris Biopharma Holdings's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=13.689+369.838
=383.5

Xeris Biopharma Holdings's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=13.011+379.002
=392.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $392.0 Mil mean?
Xeris Biopharma Holdings (XERS) has a Total Assets of $392.0 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Xeris Biopharma Holdings and its competitors.
Is Xeris Biopharma Holdings' Total Assets too high?
Xeris Biopharma Holdings' current Total Assets is $392.0 Mil. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Total Assets compare to PAHC and PRGO?
Xeris Biopharma Holdings' Total Assets of $392.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Xeris Biopharma Holdings and its competitors. Xeris Biopharma Holdings's current Total Assets is $392.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.20, compared to a current price of $8.55 — trading 64.4% above its estimated fair value. The current Total Assets is $392.0 Mil. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current Total Assets is $392.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?

Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued. The current stock price of $8.55 is trading 64.4% above its estimated GF Value™ of $5.20. GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.

Key valuation signals for XERS:

  • Total Assets: $392.0 Mil
  • GF Value™: $5.20 vs. price of $8.55 (64.4% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xeris Biopharma Holdings Business Description

Other Exchanges 0A8E:UK2B30:Germany
Address 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score

Get the complete analysis for XERS

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.55
Price
$5.20
GF Value